Anchor your review to decision points, not tumor lists: learn each staging framework, the molecular classifiers that override histology, and which modality each classification selects. Then test yourself with written scenarios where two plausible pathways share the same presentation.
One Cancer, Three Staging Frameworks: Choosing the Right Map
Endometrial, cervical, and ovarian cancers each follow a distinct FIGO staging logic, and mixing these logics produces wrong treatment answers even when your individual facts are correct.
Endometrial carcinoma staging (FIGO 2023) now integrates molecular classification alongside anatomic extent, so two histologically identical tumors can land in different stages based on POLE mutation, mismatch repair deficiency, or p53 abnormality. Cervical cancer staging (FIGO 2018) permits imaging and pathology findings and is defined by tumor size and local extension. Ovarian cancer remains a surgical-pathologic stage determined by what staging surgery finds.
Train yourself to name the framework before answering any staging question. Ask: which organ, which FIGO version, and what information does the framework actually use? A cervical stage cannot depend on molecular markers; an endometrial stage can. A clinical ovarian cancer stage assigned before surgery is provisional. Writing this three-step identification aloud before each practice answer builds the habit that prevents framework cross-contamination.
| Cancer | Staging basis | Key stage driver | Main treatment pivot |
|---|---|---|---|
| Endometrial (FIGO 2023) | Anatomic extent plus molecular class | POLEmut / MMRd / p53abn / NSMP | Adjuvant therapy intensity and radiation field |
| Cervical (FIGO 2018) | Clinical with imaging and pathology permitted | Tumor size and local extension | Radical surgery for small early tumors vs chemoradiation |
| Ovarian | Surgical-pathologic findings | Distribution beyond pelvis and residual disease | Primary debulking vs neoadjuvant chemotherapy |
Scenario: An Endometrial Biopsy That Changes Adjuvant Therapy
In this scenario, a same-grade endometrioid adenocarcinoma is reclassified by molecular testing, and the adjuvant decision must follow the classifier, not the original histologic impression.
The case: a 62-year-old woman undergoes hysterectomy for a grade 2 endometrioid endometrial carcinoma confined to the corpus with less than half myometrial invasion on frozen section. The team initially plans no adjuvant therapy. Final testing returns a pathogenic POLE exonuclease-domain mutation. The tempting mistake is to dismiss the result because the tumor looks low risk anatomically and to add radiation 'just in case.'
The better decision is to place the tumor into the low-risk end of the molecular staging framework: POLE-mutated tumors at low anatomic stage are generally managed with observation, and escalating therapy adds morbidity without established benefit. Contrast this with a p53-abnormal tumor of the same anatomic extent, which the framework moves toward a higher-risk category and intensified adjuvant discussion. The lesson is that the molecular classifier is not a supplementary fact — it is a stage-setting input, and your adjuvant reasoning should start from it.
Scenario: The Post-Chemoradiation Hysterectomy Trap in Cervical Cancer
After definitive chemoradiation with brachytherapy for locally advanced cervical cancer, routine adjuvant extrafascial hysterectomy is the classic tempting-but-incorrect add-on in scenario questions.
The case: a 47-year-old woman with a 5 cm cervical squamous carcinoma, FIGO stage IB3, completes pelvic external beam radiation with weekly platinum-based chemotherapy plus brachytherapy. Follow-up imaging shows a residual soft-tissue density in the cervix. The plausible mistake is to recommend adjuvant hysterectomy to 'convert a partial response into a cure' or out of anxiety about residual post-treatment findings.
The better decision is to complete the planned combined-modality treatment and evaluate the residual finding appropriately — post-radiation changes can mimic persistent tumor, and hysterectomy after full-dose radiation adds substantial surgical morbidity without an established survival gain in this setting. The management error that matters conceptually is adding a second modality where brachytherapy is already the dose-escalation tool. Recognize the pattern: when definitive radiation with brachytherapy is the chosen pathway, surgery is not a rescue layer unless persistent viable disease is actually demonstrated.
Matching Systemic Therapy to Biomarker, Not Just Histology
Systemic therapy decisions in gynecologic oncology split into cytotoxic backbones, anti-angiogenic agents, PARP inhibitors, and biomarker-selected immunotherapy — each with its own eligibility logic.
Platinum-doublet chemotherapy remains the backbone for epithelial ovarian cancer and for recurrent disease across several sites, but maintenance strategy is biomarker-driven: PARP inhibitor maintenance is tied to BRCA mutation or homologous recombination deficiency in the ovarian setting, while anti-angiogenic therapy such as bevacizumab is selected by clinical features rather than a germline test. Immunotherapy selection keys on mismatch repair deficiency or high microsatellite instability, which is why the MMRd category appears in both the staging framework and the systemic therapy framework.
Practice expressing each agent as a conditional: agent plus trigger plus setting. 'PARP inhibitor maintenance after platinum response in BRCA-mutated or HRD-positive ovarian cancer' is a usable knowledge unit; 'PARP inhibitors are used in ovarian cancer' is not, because it cannot answer a scenario that changes the biomarker. Drill by taking one agent and deliberately varying the trigger — BRCA wild-type, platinum-refractory disease, MSI-proficient tumor — and articulating how the recommendation changes.
- Cytotoxic backbone: platinum-doublet pairing and rechallenge logic tied to platinum-sensitive versus platinum-resistant intervals
- Anti-angiogenic: selected by clinical risk features, not a single biomarker test
- PARP inhibition: anchored to BRCA or homologous recombination deficiency status in the ovarian maintenance setting
- Immunotherapy: anchored to MMR/MSI status, which links directly back to the endometrial molecular classifier
Brachytherapy Versus EBRT: Two Roles Candidates Mix Up
External beam radiation treats the pelvis at risk; brachytherapy escalates dose to the cervix itself. The two are complementary, and questions probe whether you know which one answers which problem.
In locally advanced cervical cancer, external beam radiation with concurrent chemotherapy addresses the primary tumor and pelvic nodal basins, while brachytherapy delivers the final dose escalation directly to the cervix and parametria — a role external fields cannot replicate without unacceptable bladder and bowel dose. Knowing that brachytherapy is central, not optional, changes how you answer any scenario that offers 'complete external beam and observe' versus 'complete treatment including brachytherapy.'
In endometrial cancer the split is different: vaginal brachytherapy alone can be an adjuvant option for selected intermediate-risk disease because the dominant recurrence pattern is vaginal, while external beam is reserved for broader pelvic risk. This contrast is the point worth memorizing — the same technique plays a central definitive role in one disease and a narrower adjuvant role in the other. When you review radiation, write one sentence per disease stating what brachytherapy is responsible for, then check it against the staging framework from section one.
Surgical Radicality Decisions: How Much Is Enough
Surgical questions turn on matching radicality to tumor size and spread: conization or simple hysterectomy at the low end, radical hysterectomy and nodal assessment in the middle, and debulking logic for ovarian disease.
For early cervical cancer, smaller tumors may permit cone biopsy or simple hysterectomy, while larger early tumors require radical hysterectomy with removal of parametrial tissue and pelvic lymph node assessment, often with sentinel node mapping. Fertility preservation introduces a further fork: radical trachelectomy is the option discussed for small, early tumors in patients who wish to retain fertility. Each cut point exists because parametrial involvement and nodal spread risk rise with tumor size.
Ovarian surgery follows a different axis: the goal is complete gross resection, so the real decision is primary debulking surgery versus neoadjuvant chemotherapy followed by interval debulking, guided by disease distribution and whether complete resection is achievable. Notice the shared structure with cervical surgery — the surgical choice encodes a probability of spread — but the endpoint differs, cure through resection upfront versus cytoreduction timed around systemic therapy. Comparing these axes side by side is more useful than memorizing each operation in isolation.
A Two-Week Self-Test Cycle and Readiness Rubric
Convert the frameworks above into a repeating cycle: build one decision map per topic, write a scenario that forces a fork, answer in writing, and score yourself against explicit observations.
Exercise: pick one tumor type per study day. Draw its staging framework, list the biomarkers that modify stage or therapy, then write a short vignette with a deliberate trap — for example, a POLE-mutated tumor that 'looks' like it needs radiation, or residual cervical finding after chemoradiation that tempts surgery. Answer your own vignette in writing before consulting references. Expected observation: your first unprompted answers should name the staging framework and the molecular classifier within the first two sentences; if they do not, the trap worked on you.
Adaptable sequence: weeks one and two, build the three staging maps and the biomarker-to-agent table from memory, one cancer per day with next-day re-drawing. Weeks three and four, rotate through the six topic areas writing one fork scenario each and scoring it. Readiness checks, which are learning milestones rather than pass predictions: you can redraw the comparison table from section one unaided; you can state the trigger and setting for each systemic agent in the bullets; your written scenario answers name a framework before naming a treatment; and when given two plausible pathways for one vignette, you can articulate why the rejected pathway fails. For administrative details about the credential itself, consult the issuer at https://www.abog.org/.
References and further reading
Use these references to explore the concepts and check the latest information from the relevant organizations.